[Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology]

V Sibaud; J-P Delord; C Chevreau; D Gangloff; I Garrido-Stowhas

doi:10.1016/j.anplas.2012.02.002

[Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology]

Ann Chir Plast Esthet. 2012 Apr;57(2):106-13. doi: 10.1016/j.anplas.2012.02.002. Epub 2012 Mar 15.

[Article in French]

Authors

V Sibaud¹, J-P Delord, C Chevreau, D Gangloff, I Garrido-Stowhas

Affiliation

¹ Dermatologie, centre de lutte contre le cancer, institut Claudius Regaud, Toulouse, France. sibaud.vincent@claudiusregaud.fr

PMID: 22425393
DOI: 10.1016/j.anplas.2012.02.002

Abstract

The management of oncology patients has been deeply modified over recent years by the development of new targeted anticancer therapies. Though these new therapies generally have a good safety profile, the skin is probably the organ most affected by their toxicity, in terms of frequency and symptom diversity. This review describes the most frequent cutaneous side effects induced by the new targeted therapies used in oncodermatology, whether they are well-established drugs such as EGF receptor inhibitors (cetuximab, erlotinib) or imatinib, or new treatments for metastatic melanoma such as selective BRAF (vemurafenib) or MEK inhibitors (selumetinib) and CTLA-4 monoclonal antibodies (ipilimumab).

Publication types

Review

MeSH terms

Antineoplastic Agents / adverse effects*
Drug Eruptions / etiology*
ErbB Receptors / antagonists & inhibitors
Humans
Molecular Targeted Therapy / adverse effects*
Skin Neoplasms / drug therapy*
raf Kinases / antagonists & inhibitors

Substances

Antineoplastic Agents
ErbB Receptors
raf Kinases